No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
www.fdcindia.comNo one on the platform currently holds FDC.NS.
No tracked institution reports a position in FDC.NS as of their last filing.
No one on the platform has traded FDC.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.8% | 9.1% | 10.6% | — | — | — |
| Rev. Growth % | 3.0% | 10.3% | ||||
| Profit Margin % | 13.0% | 13.3% | 15.8% | |||
| Free Cash Flow Margin % | 2.9% | 5.3% | 8.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2029 | $11.7B | — | $12.30 | $12.30–$12.30 | — | 1 |
| 2030 | $13.4B | +14.6% | $13.50 | $13.50–$13.50 | — | 1 |
| 2031 | $14.6B | +9.3% | $19.20 | $19.20–$19.20 | — | 1 |
| 2032 | $15.8B | +7.8% | $17.60 | $17.60–$17.60 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| FDC.NSFDC Limited | $349.65 | +2.40% | $56.9B | — |
| AARTIPHARM.BOAarti Pharmalabs Limited | $789.30 | -4.55% | $71.2B | — |
| AARTIPHARM.NSAarti Pharmalabs Limited | $789.45 | -4.53% | $71.6B | — |
| KOVAI.BOKovai Medical Center and Hospital Limited | $6014.60 | -3.29% | $65.8B | — |
| MARKSANS.BOMarksans Pharma Limited |
| $312.40 |
| -4.84% |
| $141.6B |
| — |
| MARKSANS.NSMarksans Pharma Limited | $312.85 | -5.02% | $141.8B | — |
| SHILPAMED.NSShilpa Medicare Limited | $911.90 | -5.12% | $178.4B | — |
Source: Financial Modeling Prep · peers by sector/industry